

INZYMES ApS

Strandvejen 125, 2900 Hellerup

CVR-nr. 44 27 21 13
Company reg. no. 44 27 21 13

Årsrapport *Annual report*

1. januar - 31. december 2024
1 January - 31 December 2024

Årsrapporten er fremlagt og godkendt på selskabets ordinære generalforsamling den 6. maj 2025.
The annual report was submitted and approved by the general meeting on the 6 May 2025.

Michael Fooker Jensen
Dirigent
Chairman of the meeting



Indholdsfortegnelse

Contents

	Side <u>Page</u>
Påtegninger	
<i>Reports</i>	
Ledelsespåtegning	1
<i>Management's statement</i>	
Revisors erklæring om opstilling af årsregnskab	3
<i>Practitioner's compilation report</i>	
Ledelsesberetning	
<i>Management's review</i>	
Selskabsoplysninger	5
<i>Company information</i>	
Ledelsesberetning	6
<i>Management's review</i>	
Årsregnskab 1. januar - 31. december 2024	
<i>Financial statements 1 January - 31 December 2024</i>	
Resultatopgørelse	7
<i>Income statement</i>	
Balance	8
<i>Balance sheet</i>	
Egenkapitalopgørelse	10
<i>Statement of changes in equity</i>	
Noter	11
<i>Notes</i>	
Anvendt regnskabspraksis	12
<i>Accounting policies</i>	

Notes to users of the English version of this document:

- This document contains a Danish version as well as an English version. In the event of any dispute regarding the interpretation of any part of the document, the Danish version of the document shall prevail.
- To ensure the greatest possible applicability of the English version of the document, IAS/IFRS English terminology has been used.
- Please note that decimal points remain unchanged from Danish version of the document. This means that DKK 146.940 corresponds to the English amount of DKK 146,940, and that 23,5 % corresponds to 23.5 %.



Ledelsespåtegning *Management's statement*

Bestyrelse og direktion har dags dato aflagt årsrapporten for regnskabsåret 1. januar - 31. december 2024 for INZYMES ApS.

Today, the Board of Directors and the Executive Board have approved the annual report of INZYMES ApS for the financial year 1 January - 31 December 2024.

Årsrapporten er aflagt i overensstemmelse med årsregnskabsloven.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

Vi anser den valgte regnskabspraksis for hensigtsmæssig, og efter vores opfattelse giver årsregnskabet et retvisende billede af selskabets aktiver, passiver og finansielle stilling pr. 31. december 2024 samt af resultatet af selskabets aktiviteter for regnskabsåret 1. januar - 31. december 2024.

We consider the chosen accounting policy to be appropriate, and in our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January – 31 December 2024.

Bestyrelse og direktion anser betingelserne for at undlade revision af årsregnskabet for 2024 for opfyldt.

The Board of Directors and the Executive Board consider the conditions for audit exemption of the 2024 financial statements to be met.

Ledelsesberetningen indeholder efter vores opfattelse en retvisende redegørelse for de forhold, som beretningen omhandler.

Further, in our opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.

Årsrapporten indstilles til generalforsamlingens godkendelse.

We recommend that the annual report be approved at the Annual General Meeting.

Hellerup, den 28. april 2025

Hellerup, 28 April 2025

Direktion

Executive board

Jonas Jacobsen

Johannes Maarten van den Brink Michael Fooken Jensen



Ledelsespåtegning *Management's statement*

Bestyrelse

Board of directors

Carlo Appennini
Formand
Chairman

Johannes Maarten van den Brink Michael Fooken Jensen

Iris Verga

Viola Verga



Revisors erklæring om opstilling af årsregnskab *Practitioner's compilation report*

Til kapitalejerne i INZYMES ApS

Vi har opstillet årsregnskabet for INZYMES ApS for regnskabsåret 1. januar - 31. december 2024 på grundlag af selskabets bogføring og øvrige oplysninger, som De har tilvejebragt.

Årsregnskabet omfatter anvendt regnskabspraksis, resultatopgørelse, balance, egenkapitalopgørelse og noter.

Vi har udført opgaven i overensstemmelse med ISRS 4410, Opgaver om opstilling af finansielle oplysninger.

Vi har anvendt vores faglige ekspertise til at assistere Dem med at udarbejde og præsentere årsregnskabet i overensstemmelse med årsregnskabsloven. Vi har overholdt relevante bestemmelser i revisorloven og International Ethics Standards Board for Accountants' internationale retningslinjer for revisorerets etiske adfærd (IESBA Code), herunder principper om integritet, objektivitet, professionel kompetence og fornøden omhu.

Årsregnskabet samt nøjagtigheden og fuldstændigheden af de oplysninger, der er anvendt til opstillingen af årsregnskabet, er Deres ansvar.

To the Shareholders of INZYMES ApS

We have compiled the financial statements of INZYMES ApS for the financial year 1 January - 31 December 2024 based on the company's bookkeeping and on information you have provided.

These financial statements comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist Management in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements under the Danish Act on Approved Auditors and Audit Firms and International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.



Revisors erklæring om opstilling af årsregnskab *Practitioner's compilation report*

Da en opgave om opstilling af finansielle oplysninger ikke er en erklæringsopgave med sikkerhed, er vi ikke forpligtet til at verificere nøjagtigheden eller fuldstændigheden af de oplysninger, De har givet os til brug for at opstille årsregnskabet. Vi udtrykker derfor ingen revisions- eller reviewkonklusion om, hvorvidt årsregnskabet er udarbejdet i overensstemmelse med årsregnskabsloven.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with the Danish Financial Statements Act.

København, den 28. april 2025
Copenhagen, 28 April 2025

Christensen Kjarulff
Statsautoriseret Revisionsaktieselskab
CVR-nr. 15 91 56 41
Company reg. no. 15 91 56 41

Anders Ingemann Hansen
statsautoriseret revisor
State Authorised Public Accountant
mne32726



Selskabsoplysninger *Company information*

Selskabet <i>The company</i>	INZYMES ApS Strandvejen 125 2900 Hellerup
	E-mail: info@inzymes.com <i>E mail</i>
	CVR-nr.: 44 27 21 13 <i>Company reg. no.</i>
	Stiftet: 1. september 2023 <i>Established: 1 September 2023</i>
	Regnskabsår: 1. januar - 31. december <i>Financial year: 1 January - 31 December</i>
Bestyrelse <i>Board of directors</i>	Carlo Appennini, Formand, <i>Chairman</i> Johannes Maarten van den Brink Michael Fooken Jensen Iris Verga Viola Verga
Direktion <i>Executive board</i>	Jonas Jacobsen Johannes Maarten van den Brink Michael Fooken Jensen
Revisor <i>Auditors</i>	Christensen Kjærulff Statsautoriseret Revisionsaktieselskab Østbanegade 123 2100 København Ø
Modervirksomhed <i>Parent company</i>	SACCO S.R.L. VAT number: IT36448725 Country: Italy



Ledelsesberetning *Management's review*

Selskabets væsentligste aktiviteter

Selskabets aktivitet har bestået af udvikling, produktion og salg af ingredienser til fødevarer samt anden dermed efter direktionens skøn beslægtet virksomhed.

Væsentlige ændringer i virksomhedens aktiviteter og økonomiske forhold

Årets bruttotab udgør -5.297 t.kr. mod -4.618 t.kr. sidste år. Det ordinære resultat efter skat udgør -7.167 t.kr. mod -5.794 t.kr. sidste år. Ledelsen anser årets resultat som forventet.

Description of key activities of the company

Like previous years, the activities are the development, production and sale of food ingredients and other related activities according to the Management.

Significant changes in the company's activities and financial matters

The gross loss for the year totals DKK -5.297thousand against DKK -4.618thousand last year. Income or loss from ordinary activities after tax totals DKK -7.167thousand against DKK -5.794thousand last year. Management considers the net profit or loss for the year as expected.



Resultatopgørelse Income statement

All amounts in DKK.

Note	1/1 - 31/12 2024	1/9 - 31/12 2023
Bruttotab <i>Gross loss</i>	-5.296.729	-4.618.486
1 Personaleomkostninger <i>Staff costs</i>	-5.222.168	-1.194.797
Driftsresultat <i>Operating profit</i>	-10.518.897	-5.813.283
Andre finansielle indtægter <i>Other financial income</i>	383.452	22.583
2 Øvrige finansielle omkostninger <i>Other financial expenses</i>	-1.186	-2.889
Resultat før skat <i>Pre-tax net profit or loss</i>	-10.136.631	-5.793.589
Skat af årets resultat <i>Tax on net profit or loss for the year</i>	2.969.956	0
Årets resultat <i>Net profit or loss for the year</i>	-7.166.675	-5.793.589
Forslag til resultatdisponering: <i>Proposed distribution of net profit:</i>		
Disponeret fra overført resultat <i>Allocated from retained earnings</i>	-7.166.675	-5.793.589
Disponeret i alt <i>Total allocations and transfers</i>	-7.166.675	-5.793.589



Balance 31. december
Balance sheet at 31 December

All amounts in DKK.

Aktiver <i>Assets</i>	2024	2023
Note	<u> </u>	<u> </u>
Anlægsaktiver <i>Non-current assets</i>		
3 Deposita <i>Deposits</i>	45.000	22.796
Finansielle anlægsaktiver i alt <i>Total investments</i>	<u>45.000</u>	<u>22.796</u>
Anlægsaktiver i alt <i>Total non-current assets</i>	<u>45.000</u>	<u>22.796</u>
Omsætningsaktiver <i>Current assets</i>		
Tilgodehavende selskabsskat <i>Income tax receivables</i>	2.969.956	0
Andre tilgodehavender <i>Other receivables</i>	29.569	42.934
Periodeafgrænsningsposter <i>Prepayments</i>	<u>45.000</u>	<u>11.398</u>
Tilgodehavender i alt <i>Total receivables</i>	<u>3.044.525</u>	<u>54.332</u>
Likvide beholdninger <i>Cash and cash equivalents</i>	<u>7.401.223</u>	<u>16.731.186</u>
Omsætningsaktiver i alt <i>Total current assets</i>	<u>10.445.748</u>	<u>16.785.518</u>
Aktiver i alt <i>Total assets</i>	<u>10.490.748</u>	<u>16.808.314</u>



Balance 31. december

Balance sheet at 31 December

All amounts in DKK.

Passiver <i>Equity and liabilities</i>	<u>2024</u>	<u>2023</u>
Note		
Egenkapital <i>Equity</i>		
Virksomhedskapital <i>Contributed capital</i>	133.333	133.333
Overført resultat <i>Retained earnings</i>	<u>9.318.863</u>	<u>16.485.538</u>
Egenkapital i alt <i>Total equity</i>	<u>9.452.196</u>	<u>16.618.871</u>
Gældsforpligtelser <i>Liabilities other than provisions</i>		
Gæld til pengeinstitutter <i>Bank loans</i>	276	13.667
Leverandører af varer og tjenesteydelser <i>Trade payables</i>	19.349	15.000
Anden gæld <i>Other payables</i>	<u>1.018.927</u>	<u>160.776</u>
Kortfristede gældsforpligtelser i alt <i>Total short term liabilities other than provisions</i>	<u>1.038.552</u>	<u>189.443</u>
Gældsforpligtelser i alt <i>Total liabilities other than provisions</i>	<u>1.038.552</u>	<u>189.443</u>
Passiver i alt <i>Total equity and liabilities</i>	<u>10.490.748</u>	<u>16.808.314</u>



Egenkapitaloppgørelse *Statement of changes in equity*

All amounts in DKK.

	Virksomheds- kapital <i>Contributed capital</i>	Overkurs ved emission <i>Share premium</i>	Overført resultat <i>Retained earnings</i>	I alt <i>Total</i>
	<hr/>	<hr/>	<hr/>	<hr/>
Egenkapital 1. september 2023 <i>Equity 1 September 2023</i>	40.000	0	0	40.000
Kontant kapitaludvidelse <i>Cash capital increase</i>	93.333	22.279.127	0	22.372.460
Årets overførte overskud eller underskud <i>Retained earnings for the year</i>	0	0	-5.793.589	-5.793.589
Overført til overført resultat <i>Transferred to retained earnings</i>	0	-22.279.127	22.279.127	0
	<hr/>	<hr/>	<hr/>	<hr/>
Egenkapital 1. januar 2024 <i>Equity 1 January 2024</i>	133.333	0	16.485.538	16.618.871
Årets overførte overskud eller underskud <i>Retained earnings for the year</i>	0	0	-7.166.675	-7.166.675
	<hr/>	<hr/>	<hr/>	<hr/>
	133.333	0	9.318.863	9.452.196



Noter Notes

All amounts in DKK.

	1/1 - 31/12 2024	1/9 - 31/12 2023
1. Personalemkostninger <i>Staff costs</i>		
Lønninger og gager <i>Salaries and wages</i>	4.837.506	1.065.108
Pensioner <i>Pension costs</i>	362.426	126.849
Andre omkostninger til social sikring <i>Other costs for social security</i>	22.236	2.840
	5.222.168	1.194.797
Gennemsnitligt antal beskæftigede medarbejdere <i>Average number of employees</i>	3	3
2. Øvrige finansielle omkostninger <i>Other financial expenses</i>		
Andre finansielle omkostninger <i>Other financial costs</i>	1.186	2.889
	1.186	2.889
3. Deposita <i>Deposits</i>		
Kostpris 1. januar 2024 <i>Cost 1 January 2024</i>	22.796	0
Tilgang i årets løb <i>Additions during the year</i>	45.000	22.796
Afgang i årets løb <i>Disposals during the year</i>	-22.796	0
Kostpris 31. december 2024 <i>Cost 31 December 2024</i>	45.000	22.796
Regnskabsmæssig værdi 31. december 2024 <i>Carrying amount, 31 December 2024</i>	45.000	22.796



Anvendt regnskabspraksis *Accounting policies*

Årsrapporten for INZYMES ApS er aflagt i overensstemmelse med årsregnskabslovens bestemmelser for en klasse B-virksomhed. Herudover har virksomheden valgt at følge enkelte regler for klasse C-virksomheder.

Årsrapporten er aflagt efter samme regnskabspraksis som sidste år og aflægges i danske kroner.

Generelt om indregning og måling

I resultatopgørelsen indregnes indtægter i takt med, at de indtjenes. Herunder indregnes værdireguleringer af finansielle aktiver og forpligtelser. I resultatopgørelsen indregnes ligeledes alle omkostninger, herunder afskrivninger, nedskrivninger og hensatte forpligtelser samt tilbageførsler som følge af ændrede regnskabsmæssige skøn af beløb, der tidligere har været indregnet i resultatopgørelsen.

Aktiver indregnes i balancen, når det er sandsynligt, at fremtidige økonomiske fordele vil tilflyde selskabet, og aktivets værdi kan måles pålideligt.

Forpligtelser indregnes i balancen, når det er sandsynligt, at fremtidige økonomiske fordele vil fragå selskabet, og forpligtelsens værdi kan måles pålideligt.

Ved første indregning måles aktiver og forpligtelser til kostpris. Efterfølgende måles aktiver og forpligtelser som beskrevet nedenfor for hver enkelt regnskabspost.

The annual report for INZYMES ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Recognition and measurement in general

Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, write-downs for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.

Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.

Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.

Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.



Anvendt regnskabspraksis

Accounting policies

Ved indregning og måling tages hensyn til forudsigelige tab og risici, der fremkommer inden årsrapporten aflægges, og som vedrører forhold, der eksisterede på balancedagen.

Resultatopgørelsen

Bruttotab

Bruttotab indeholder omsætning, direkte omkostninger samt eksterne omkostninger.

Nettoomsætning indregnes i resultatopgørelsen, såfremt levering og risikoovergang til køber har fundet sted inden årets udgang, og såfremt indtægten kan opgøres pålideligt og forventes modtaget. Nettoomsætningen måles til dagsværdien af det aftalte vederlag eksklusiv moms og afgifter og med fradrag af rabatter i forbindelse med salget.

Vareforbrug omfatter omkostninger til køb af råvarer og hjælpematerialer med fradrag af rabatter samt årets forskydning i varebeholdninger.

Andre eksterne omkostninger omfatter omkostninger til salg, administration og lokaler.

Personaleomkostninger

Personaleomkostninger omfatter løn og gager, inklusive feriepenge og pensioner samt andre omkostninger til social sikring mv. til selskabets medarbejdere.

Upon recognition and measurement, allowances are made for such predictable losses and risks which may arise prior to the presentation of the annual report and concern matters that exist on the reporting date.

Income statement

Gross loss

Gross loss comprises the direct costs and external costs.

Revenue is recognised in the income statement if delivery and passing of risk to the buyer have taken place before the end of the year and if the income can be determined reliably and inflow is anticipated. Revenue is measured at the fair value of the consideration promised exclusive of VAT and taxes and less any discounts relating directly to sales.

Cost of sales comprises costs concerning purchase of raw materials and consumables less discounts and changes in inventories.

Other external expenses comprise expenses incurred for sales, administration and premises.

Staff costs

Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members.



Anvendt regnskabspraksis *Accounting policies*

Finansielle indtægter og omkostninger

Finansielle indtægter og omkostninger indregnes i resultatopgørelsen med de beløb, der vedrører regnskabsåret. Finansielle poster omfatter renteindtægter og -omkostninger og realiserede og urealiserede kursgevinster og kurstab vedrørende transaktioner i fremmed valuta.

Skat af årets resultat

Årets skat, der består af årets aktuelle selskabsskat og ændring i udskudt skat, indregnes i resultatopgørelsen med den del, der kan henføres til årets resultat, og direkte i egenkapitalen med den del, der kan henføres til posteringer direkte i egenkapitalen.

Balancen

Finansielle anlægsaktiver

Deposita

Deposita måles til amortiseret kostpris og udgøres af huslejedeposita mv.

Tilgodehavender

Tilgodehavender måles til amortiseret kostpris, hvilket sædvanligvis svarer til nominal værdi.

Periodeafgrænsningsposter

Periodeafgrænsningsposter, som er indregnet under aktiver, omfatter afholdte omkostninger vedrørende efterfølgende regnskabsår.

Likvide beholdninger

Likvide beholdninger omfatter indeståender i pengeinstitutter.

Financial income and expenses

Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses and realised and unrealised capital gains and losses relating to transactions in foreign currency.

Tax on net profit or loss for the year

Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity.

Statement of financial position

Investments

Deposits

Deposits are measured at amortised cost and represent lease deposits, etc.

Receivables

Receivables are measured at amortised cost, which usually corresponds to nominal value.

Prepayments

Prepayments recognised under assets comprise incurred costs concerning the following financial year.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank.



Anvendt regnskabspraksis

Accounting policies

Selskabsskat og udskudt skat

Aktuelle skatteforpligtelser og tilgodehavende aktuel skat indregnes i balancen som beregnet skat af årets skattepligtige indkomst, reguleret for skat af tidligere års skattepligtige indkomster og for betalte acontoskatter.

Udskudt skat måles efter den balanceorienterede gælds metode af midlertidige forskelle mellem regnskabsmæssig og skattemæssig værdi af aktiver og forpligtelser opgjort på grundlag af den planlagte anvendelse af aktivet henholdsvis afvikling af forpligtelsen. Udskudt skat måles til nettorealiseringsværdi.

Udskudt skat måles på grundlag af de skatteregler og skattesatser i de respektive lande, der med balancedagens lovgivning vil være gældende, når den udskudte skat forventes udløst som aktuel skat. Ændring i udskudt skat som følge af ændringer i skattesatser indregnes i resultatopgørelsen bortset fra poster, der føres direkte på egenkapitalen.

Udskudte skatteaktiver, herunder skatteværdien af fremførselsberettiget skattemæssigt underskud, måles til den værdi, hvortil aktivet forventes at kunne realiseres, enten ved udligning i skat af fremtidig indtjening eller ved modregning i udskudte skatteforpligtelser inden for samme juridiske skatteenhed. Eventuelle udskudte nettoskatteaktiver måles til nettorealiseringsværdi.

Gældsforpligtelser

Øvrige gældsforpligtelser, som omfatter gæld til leverandører samt anden gæld, måles til amortiseret kostpris, hvilket sædvanligvis svarer til nominal værdi.

Income tax and deferred tax

Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Deferred tax is measured based on the tax rules and tax rates applying under the legislation prevailing in the respective countries on the reporting date when the deferred tax is expected to be released as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement, except for items included directly in the equity.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.

Liabilities other than provisions

Other liabilities concerning payables to suppliers and other payables are measured at amortised cost which usually corresponds to the nominal value.

Jonas Jacobsen

Name returned by MitId: Jonas Jacobsen
Direktør
ID: a27972df-09dd-4935-9d0e-91af6a12c2d8
IP-address: 81.114.152.150:3602
Date of signature: 06-05-2025 12:43:38 CEST (+02:00)
Signed with MitId



Johannes Maarten van den Brink

Direktør
IP-address: 81.114.152.150:27633
Date of signature: 06-05-2025 09:01:46 CEST (+02:00)
Signed with esignatur EasySign



Michael Fooken Jensen

Name returned by MitId: Michael Fooken Jensen
Direktør
ID: 74cc60a3-dfdc-4042-b8ad-59790227dec3
IP-address: 81.114.152.150:10804
Date of signature: 06-05-2025 12:44:14 CEST (+02:00)
Signed with MitId



Carlo Appennini

Bestyrelsesformand
IP-address: 81.114.152.148:41206
Date of signature: 06-05-2025 13:59:09 CEST (+02:00)
Signed with esignatur EasySign



Johannes Maarten van den Brink

Bestyrelsesmedlem
IP-address: 81.114.152.150:28149
Date of signature: 06-05-2025 12:46:12 CEST (+02:00)
Signed with esignatur EasySign



Michael Fooken Jensen

Name returned by MitId: Michael Fooken Jensen
Bestyrelsesmedlem
ID: 74cc60a3-dfdc-4042-b8ad-59790227dec3
IP-address: 81.114.152.150:19985
Date of signature: 06-05-2025 12:53:04 CEST (+02:00)
Signed with MitId



Iris Verga

Bestyrelsesmedlem
IP-address: 81.114.152.148:38399
Date of signature: 15-05-2025 10:57:54 CEST (+02:00)
Signed with esignatur EasySign



Viola Verga

Bestyrelsesmedlem
IP-address: 81.114.152.148:60764
Date of signature: 12-05-2025 11:23:19 CEST (+02:00)
Signed with esignatur EasySign



Anders Ingemann Hansen

Name returned by Mitld: Anders Ingemann Hansen

Revisor

On behalf of Christensen Kjørulff Statsautoriseret
Revisionsaktieselskab

ID: 6d7bce96-ce62-43b2-9f7d-3648380bb824

IP-address:

Date of signature: 15-05-2025 21:46:07 CEST (+02:00)

Signed with Mitld



Michael Fooken Jensen

Name returned by Mitld: Michael Fooken Jensen

Dirigent

ID: 74cc60a3-dfdc-4042-b8ad-59790227dec3

IP-address: 77.241.128.178:38532

Date of signature: 15-05-2025 23:00:01 CEST (+02:00)

Signed with Mitld



This document is signed with esignatur. Embedded in the document is the original agreement document and a signed data object for each signatory. The signed data object contains a mathematical hash value calculated from the original agreement document, which secures that the signatures is related to precisely this document only. Prove for the originality and validity of signatures can always be lifted as legal evidence.

The document is locked for changes and all cryptographic signature certificates are embedded in this PDF. The signatures therefore comply with all public recommendations and laws for digital signatures. With esignatur's solution, it is ensured that all European laws are respected in relation to sensitive information and valid digital signatures. If you would like more information about digital documents signed with esignatur, please visit our website at www.esignatur.dk.